Diphenyl diselenide and its interaction with antifungals against Aspergillus spp.

Aspergillus animal model aspergillosis checkerboard selenium synergism

Journal

Medical mycology
ISSN: 1460-2709
Titre abrégé: Med Mycol
Pays: England
ID NLM: 9815835

Informations de publication

Date de publication:
25 Aug 2020
Historique:
received: 17 05 2020
revised: 16 07 2020
accepted: 20 08 2020
entrez: 27 8 2020
pubmed: 28 8 2020
medline: 28 8 2020
Statut: aheadofprint

Résumé

Given the few antifungal classes available to treat aspergillosis, this study aimed to evaluate the in vitro antifungal activity of diphenyl diselenide (PhSe)2 alone and in combination with classical antifungals against Aspergillus spp., and its in vivo activity in a systemic experimental aspergillosis model. We performed in vitro broth microdilution assay of (PhSe)2 against 32 Aspergillus isolates; and a checkboard assay to test the interaction of this compound with itraconazole (ITC), voriconazole (VRC), amphotericin B (AMB), and caspofungin (CAS), against nine Aspergillus isolates. An experimental model of invasive aspergillosis in mice was studied, and survival curves were compared between an untreated group and groups treated with 100 mg/kg ITC, or (PhSe)2 in different dosages (10 mg/kg, 50 mg/kg and 100 mg/kg). All Aspergillus non-fumigatus and 50% of A. fumigatus were inhibited by (PhSe)2 in concentrations ≤ 64 µg/ml, with significant differences in MICs between the sections. Synergism or additive effect in the in vitro (PhSe)2 interaction with VRC and CAS was observed against the majority of isolates, and with ITC against the non-fumigatus strains. In addition to the inhibitory interaction, (PhSe)2 was able to add a fungicidal effect to CAS. Survival curves from the systemic experimental aspergillosis model demonstrated that the inoculum caused an acute and lethal infection in mice, and no treatment applied significantly prolonged survival over that of the control group. The results highlight the promising activity of (PhSe)2 against Aspergillus species, but more in vivo studies are needed to determine its potential applicability in aspergillosis treatment. The activity of diphenyl diselenide (PhSe)2 alone and in combination with itraconazole, voriconazole, and caspofungin, is described against three of the most pathogenic Aspergillus sections. (PhSe)2 may prove useful in therapy of infection in future; further study is required.

Identifiants

pubmed: 32844203
pii: 5897158
doi: 10.1093/mmy/myaa072
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.

Auteurs

Aryse Martins Melo (AM)

Microbiology and Parasitology Post-graduation program, Institute of Biology, Federal University of Pelotas, Pelotas, RS, Brazil.
Department of Infectious Diseases/Reference Unit for Parasitic and Fungal Infections, National Institute of Health, Dr. Ricardo Jorge, Lisbon, Portugal.
Mycology Laboratory, College of Medicine, Federal University of Rio Grande, Rio Grande, RS, Brazil.

Vanice Rodrigues Poester (VR)

Mycology Laboratory, College of Medicine, Federal University of Rio Grande, Rio Grande, RS, Brazil.
Health Science Post-graduation program, College of Medicine, Federal University of Rio Grande, Rio Grande, RS, Brazil.

Mariana Trapaga (M)

Mycology Laboratory, College of Medicine, Federal University of Rio Grande, Rio Grande, RS, Brazil.

Cristina Wayne Nogueira (CW)

Biological Sciences Post-graduation program, Department of Biochemistry and Molecular Biology, Center for Natural and Exact Sciences, Federal University of Santa Maria. RS, Brazil.

Gilson Zeni (G)

Biological Sciences Post-graduation program, Department of Biochemistry and Molecular Biology, Center for Natural and Exact Sciences, Federal University of Santa Maria. RS, Brazil.

Marife Martinez (M)

California Institute for Medical Research, San Jose, California, USA.

Gabriele Sass (G)

California Institute for Medical Research, San Jose, California, USA.

David A Stevens (DA)

California Institute for Medical Research, San Jose, California, USA.
Division of Infectious Diseases and Geographic Medicine, Stanford University Medical School, Stanford, California, USA.

Melissa Orzechowski Xavier (MO)

Microbiology and Parasitology Post-graduation program, Institute of Biology, Federal University of Pelotas, Pelotas, RS, Brazil.
Mycology Laboratory, College of Medicine, Federal University of Rio Grande, Rio Grande, RS, Brazil.
Health Science Post-graduation program, College of Medicine, Federal University of Rio Grande, Rio Grande, RS, Brazil.
California Institute for Medical Research, San Jose, California, USA.

Classifications MeSH